Screener
Maze Therapeutics MAZE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | (90) | (957) |
| Operating lease liabilities | (1,843) | (1,620) |
| Long-term liabilities | (1,094) | — |
| Net cash used in operating activities | (54,166) | (59,568) |
| Investing activities | ||
| Purchases of marketable securities | (186,031) | — |
| Maturities of marketable securities | 64,000 | — |
| Purchases of property and equipment | (200) | (692) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's operating cash flow?
- Maze Therapeutics (MAZE) reported operating cash flow of -$15.05M in Q2 2026.
- How has Maze Therapeutics's operating cash flow changed year-over-year?
- Maze Therapeutics's operating cash flow increased by 49.9% year-over-year, from -$30.05M to -$15.05M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Maze Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude